Kymera Therapeutics (KYMR) EBIT Margin (2019 - 2026)
Kymera Therapeutics (KYMR) reported EBIT Margin of 244.88% for Q1 2026, up 9189.0% year-over-year from 2.64% in Q1 2025, and up 92.82% quarter-over-quarter from 3411.01% in Q4 2025.
Kymera Therapeutics (KYMR) EBIT Margin (2019 - 2026) Analysis & Trends
Kymera Therapeutics (KYMR) has 8 years of EBIT Margin data on file, last reported at 244.88% in Q1 2026.
- EBIT Margin for Q1 2026 came in at 244.88%, up 9189.0% year-over-year; the trailing twelve-month figure through Mar 2026 was 697.67% (down 22518.0% YoY), and the FY2025 annual result was 891.07%, down 33526.0% from the prior year.
- EBIT Margin rose to 244.88% in Q1 2026 per KYMR's latest filing, from 3411.01% in the prior quarter.
- Over five years, EBIT Margin peaked at 40.33% in Q4 2023 and troughed at 3411.01% in Q4 2025.
- A 5-year average of 900.2% and a median of 469.92% in 2022 frame the typical range for EBIT Margin.
- On a YoY basis, EBIT Margin climbed as much as 22541 bps in 2025 and fell as far as 231884 bps in 2025.
- A 5-year view of EBIT Margin shows it stood at 239.36% in 2022, then surged by 83 bps to 40.33% in 2023, then sank by 2608 bps to 1092.17% in 2024, then plunged by 212 bps to 3411.01% in 2025, then surged by 93 bps to 244.88% in 2026.
- Business Quant data shows KYMR's EBIT Margin at 244.88% in Q1 2026, 3411.01% in Q4 2025, and 3347.36% in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBIT Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 925,601.88 Bn | 925,601.85 Bn | - | - |
| 2 | Belite Bio | 58,560.00 Bn | 58,560.00 Bn | - | - |
| 3 | Quantum Biopharma | 17,284.41 Bn | 17,284.40 Bn | - | - |
| 4 | Legend Biotech | 2,809.00 Bn | 2,808.71 Bn | 242.10 Mn | -6.43% |
| 5 | Evaxion A | 1,334.43 Bn | 1,334.42 Bn | - | - |
| 6 | Akari Therapeutics | 1,312.27 Bn | 1,312.26 Bn | - | - |
| 7 | Psyence Biomedical | 212.16 Bn | 212.16 Bn | - | - |
| 8 | Vertex Pharmaceuticals | 114.83 Bn | 107.58 Bn | 2.59 Bn | 38.10% |
| 9 | Abivax | 91.96 Bn | 91.96 Bn | - | - |
| 10 | Kymera Therapeutics | 8.84 Bn | 8.19 Bn | - | -244.88% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -244.88% |
| Dec 31, 2025 | -3,411.01% |
| Sep 30, 2025 | -3,347.36% |
| Jun 30, 2025 | -736.82% |
| Mar 31, 2025 | -336.77% |
| Dec 31, 2024 | -1,092.17% |
| Sep 30, 2024 | -1,927.93% |
| Jun 30, 2024 | -198.54% |
| Mar 31, 2024 | -562.18% |
| Dec 31, 2023 | -40.33% |
| Sep 30, 2023 | -1,216.35% |
| Jun 30, 2023 | -262.72% |
| Mar 31, 2023 | -478.83% |
| Dec 31, 2022 | -239.36% |
| Sep 30, 2022 | -469.92% |
| Jun 30, 2022 | -354.44% |
| Mar 31, 2022 | -383.84% |
| Dec 31, 2021 | -222.55% |
| Sep 30, 2021 | -140.82% |
| Jun 30, 2021 | -133.54% |